Profile image
Story Views

Last Hour:
Last 24 Hours:

Angsana’s RNA-based fusions cancer panel selected for Ignyta’s STARTRK2 clinical trial in Asia-Pacific

Friday, March 3, 2017 4:46
% of readers think this story is Fact. Add your two cents.

Latest News

SINGAPORE – Media OutReach – Mar 3, 2017 – Angsana Molecular & Diagnostics has announced today that it will be a partner molecular test laboratory for STARTRK-2 clinical trial sites in Asia working with Ignyta, Inc., (NASDAQ: RXDX), a biotechnology company focused on precision medicine in oncology. Angsana Molecular & Diagnostics’ RNA-based fusions cancer panel will be used for screening TRK, ROS1 and ALK fusions in the STARTRK-2 clinical trial, a registration-enabling global Phase 2 basket clinical trial for entrectinib, Ignyta’s investigational, orally available, CNS-active tyrosine kinase inhibitor targeting tumors that harbor TRK, ROS1 or ALK fusions.


Phase 1 data recently published online in Cancer Discovery showed entrectinib to be well tolerated, with responses observed in non-small cell lung cancer (NSCLC), colorectal cancer, mammary analog secretory carcinoma (MASC), melanoma and renal cell carcinoma as early as four weeks after first treatment and lasting as long as 2.5 years and still ongoing. That publication reported a 79% response rate in 24 patients with TRK, ROS1, or ALK-driven extracranial solid tumors, and showed entrectinib responses to be both rapid and durable in patients with advanced solid tumors across multiple histologies and each of the molecular targets of interest, including in multiple patients with metastatic CNS disease.

“Ignyta is excited to partner with Angsana to conduct diagnostic screening at our STARTRK-2 clinical trial sites in Asia, which will help us get entrectinib to patients with tumors driven by TRK, ROS1 or ALK fusions,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta. “Entrectinib is the only TRK inhibitor to have published data demonstrating RECIST responses in NSCLC and in patients with cancer in the CNS. The anti-tumor activity seen across cancer types and entrectinib’s ability to treat bulky CNS disease, particularly important given the propensity for many solid tumors to metastasize to the brain, is extremely encouraging,” continued Dr. Lim.

“The era of the shift away from one-size-fits-all, trial-and-error medicine, toward a health care system that utilizes molecular information to improve outcomes and make the health care system more efficient, has finally arrived to Asia Pacific especially in the area of targeted therapy for oncology,” says Dr. Chris Tan, Chief Executive Officer and founder of Angsana Molecular & Diagnostics. Dr. Chris Tan added that our College of American Pathologists (CAP) accredited molecular laboratories in Singapore and Hong Kong, turnaround time and cost efficiency are critical to support Ignyta for their STARTRK-2 trial in Singapore and Asia.


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.